Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Viridian Therapeutics Inc (NASDAQ: VRDN) closed the day trading at $19.55 up 0.62% from the previous closing price of $19.43. In other words, the price has increased by $0.62 from its previous closing price. On the day, 0.61 million shares were traded. VRDN stock price reached its highest trading level at $20.0641 during the session, while it also had its lowest trading level at $19.0.
Ratios:
For a better understanding of VRDN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.01 and its Current Ratio is at 11.01. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 27 ’24 when Beetham Thomas W. bought 5,000 shares for $23.41 per share. The transaction valued at 117,050 led to the insider holds 6,000 shares of the business. Mahoney Stephen F. bought 21,400 shares of VRDN for $499,262 on Sep 27 ’24. The President and CEO now owns 21,400 shares after completing the transaction at $23.33 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1596499200 and an Enterprise Value of 1245109376. For the stock, the TTM Price-to-Sale (P/S) ratio is 5321.66 while its Price-to-Book (P/B) ratio in mrq is 4.89. Its current Enterprise Value per Revenue stands at 4082.326 whereas that against EBITDA is -3.355.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.52, which has changed by -0.07652336 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 8.10%, while the 200-Day Moving Average is calculated to be 19.01%.
Shares Statistics:
Over the past 3-months, VRDN traded about 785.14K shares per day on average, while over the past 10 days, VRDN traded about 739020 shares per day. A total of 81.65M shares are outstanding, with a floating share count of 73.55M. Insiders hold about 9.93% of the company’s shares, while institutions hold 106.23% stake in the company. Shares short for VRDN as of 1756425600 were 11571282 with a Short Ratio of 14.74, compared to 1753920000 on 11675434. Therefore, it implies a Short% of Shares Outstanding of 11571282 and a Short% of Float of 14.799999999999999.
Earnings Estimates
The market rating of Viridian Therapeutics Inc (VRDN) is currently shaped by the ongoing analysis conducted by 11.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.42 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$2.96 and -$4.97 for the fiscal current year, implying an average EPS of -$4.05. EPS for the following year is -$3.97, with 11.0 analysts recommending between -$2.9 and -$4.99.
Revenue Estimates
Based on 14 analysts’ estimates, the company’s revenue will be $54.5M in the next fiscal year. The high estimate is $153M and the low estimate is $300k.
